Wall Street equity research analysts covering DexCom predominantly maintain a consensus Buy or Strong Buy rating, supported by secular growth trends in continuous glucose monitoring technology. Analysts frequently highlight expanding global insurance reimbursement criteria, high recurring sensor utilization rates, and robust product innovation pipelines as key justifications for maintaining positive 12-month price targets.